Lukoon

Transfection Reagents and Equipment Market: Emerging Technologies and Future Opportunities

2 min read
0
Comments
73
Views

The Transfection Reagents and Equipment Market is benefiting significantly from the rapid development of cell and gene therapies. Transfection is an essential process in numerous biotechnology workflows because it enables genetic material to be introduced into cells for research, therapeutic development, and manufacturing applications.

Market Research Future estimates that the market reached USD 1.35 billion in 2025 and is expected to grow to USD 2.59 billion by 2035, representing a CAGR of 6.75% from 2026 to 2035. The expanding pipeline of advanced therapies is expected to remain a key growth engine throughout the forecast period.

Cell and gene therapy manufacturing represents the fastest-growing application segment, with a projected CAGR of 16.1% through 2035. Increasing development of CAR-T therapies, gene-corrected treatments, and other advanced therapeutic modalities is driving demand for efficient and reproducible genetic delivery systems.

Viral methods accounted for 45.2% of the market in 2025, reflecting their established role in clinical-grade gene therapy and viral-vector production. However, physical delivery technologies are developing rapidly. Electroporation can provide a non-viral approach for cell engineering and may reduce some manufacturing constraints associated with viral vectors. The physical-method segment is projected to grow at a CAGR of 15.5%.

Equipment innovation is another important trend. High-throughput electroporation systems and microfluidic platforms are increasingly being adopted because they can improve reproducibility, processing efficiency, and scalability. Automated systems are particularly valuable for commercial manufacturing environments where consistent process performance is essential.

Contract development and manufacturing organizations are also creating new opportunities. CDMOs are increasingly involved in advanced therapy production, allowing smaller biotechnology companies to outsource complex manufacturing activities. The CDMO end-user segment is projected to grow at a CAGR of 9.8%.

Future market development will depend on the successful commercialization of advanced therapies, regulatory progress, and the availability of scalable manufacturing technologies. As cell and gene therapies move toward broader clinical adoption, demand for validated transfection reagents and equipment is expected to increase substantially.